Partial response or better at 6 months is not shown to be a prognostic indicator of progression-free survival in Waldenstrom macroglobulinemia treated with acalabrutinib: a post hoc analysis
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
waldenström macroglobulinemia,acalabrutinib,prognostic indicator,progression-free
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要